Clinical Trials Logo

Clinical Trial Summary

NIL-2 is a clinical trial designed to evaluate the efficacy and safety of low doses of Interleukin2 in the treatment of recently diagnosed, steroid dependent idiopathic nephrotic syndrome in children. Recent data suggest that Interleukin 2 could be an effective therapy via an increased production of regulatory T cells.

Clinical Trial Description

The study will include 10 children (age: 3-15 years old). Patients will receive low doses of Interleukin 2 (0.5 million UI/m²/ injection, subcutaneously).

The treatment will be initiated with an induction phase of one injection per day for 5 consecutive days, followed by a maintenance phase in which patients will receive one injection every 14 days for 6 months. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT02997150
Study type Interventional
Source University Hospital, Limoges
Status Withdrawn
Phase Phase 2
Start date February 2017
Completion date October 2018

See also
  Status Clinical Trial Phase
Recruiting NCT04585152 - Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Idiopathic Nephrotic Syndrome. Phase 2
Terminated NCT04402580 - Efficacy of Anti-CD20 Antibodies (Rituximab Biosimilar) in the Treatment of Childhood Steroid-dependent Nephrotic Syndrome Phase 2